Ulrike S Gnad-Vogt
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
Laurent J, Gnad-Vogt U, Stupp R, Quaratino S, Sessa C, Omlin A, Beck J, Gallerani E, Liedert B, Ongarello S, Bertrand C, Vicari M, Joffraud M, Gillessen Sommer S, Touvrey C, Speiser D. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med 2013; 11:5.
07.01.2013T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
07.01.2013J Transl Med 2013; 11:5
Laurent Julien, Gnad-Vogt Ulrike S, Stupp Roger, Quaratino Sonia, Sessa Cristiana, Omlin Aurelius, Beck Joachim, Gallerani Elisa, Liedert Bernd, Ongarello Stefano, Bertrand Caroline, Vicari Manuela, Joffraud Magali, Gillessen Sommer Silke, Touvrey Cedric, Speiser Daniel E
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
Gillessen S, Speiser D, Laurent J, Kramer D, Liedert B, Mattiacci M, Omlin A, Sessa C, Beck J, Gallerani E, Gnad-Vogt U, Stupp R. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur J Cancer 2012; 49:35-44.
20.08.2012A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
20.08.2012Eur J Cancer 2012; 49:35-44
Gillessen Silke, Speiser Daniel E, Laurent Julien, Kramer Daniel, Liedert Bernd, Mattiacci Maria R, Omlin Aurelius, Sessa Cristiana, Beck Joachim, Gallerani Elisa, Gnad-Vogt Ulrike S, Stupp Roger